Role of CYP 27 B 1+2838 promoter polymorphism in the treatment of chronic hepatitis B HB e A g negative with PEG ‐interferon
Author(s) -
Boglione L.,
Cusato J.,
De Nicolò A.,
Cariti G.,
Di Perri G.,
D'Avolio A.
Publication year - 2015
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12288
Subject(s) - medicine , hbsag , genotype , gastroenterology , hepatitis b virus , serology , immunology , virus , biology , gene , antibody , biochemistry
Summary In HBV ‐infected patients, the vitamin D deficiency has been related to chronic liver diseases, progression of hepatic fibrosis and poor response to the treatment. The CYP 27B1 gene, which encodes the 1‐ α ‐hidroxylase and involved in the 1,25‐dihydroxyvitamin D synthesis, was recently associated to type‐1 diabetes, autoimmune disorders and treatment response in HCV . Then, we aimed to investigate the role of CYP 27B1 polymorphisms in HBV treatment with PEG ‐ IFN . We retrospectively enrolled 190 patients with chronic hepatitis B HB eAg negative treated for 48 weeks with PEG ‐ IFN α ‐2a. We examined the role of rs4646536 CYP 27 B 1 SNP ( CYP 27 B 1+2838) according to virological and serological response. Our results showed that the TT genotype of CYP 27 B 1+2838 was significantly prevalent in patients with end‐of‐therapy virological response (37.6%) vs CT / CC (9.4%) ( P < 0.001). Virological relapse was prevalent in patients with CT / CC genotype (12.6%) vs TT genotype (2.1%) ( P < 0.001). TT genotype was also related to HB sAg loss ( P = 0.004) and anti‐ HB s appearance ( P = 0.002). In the multivariate analysis, the TT genotype resulted to be a good positive predictor of sustained virological response ( OR = 5.632, IC = 1.938–16.368, P = 0.001) and serological response ( OR = 6.161, IC = 1.856–20.457, P = 0.003). The CYP 27B1+2838 polymorphism may be useful as pretreatment factor to selection of patients with higher probability of response to therapy.